Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | JAK2 R938Q |
Therapy | Ruxolitinib |
Indication/Tumor Type | childhood B-cell acute lymphoblastic leukemia |
Response Type | resistant |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
JAK2 R938Q | childhood B-cell acute lymphoblastic leukemia | resistant | Ruxolitinib | Preclinical - Patient cell culture | Actionable | In a preclinical study, bone marrow mononuclear cells from a pediatric B-cell acute lymphoblastic leukemia with an acquired Jak2 R938Q mutation were resistant to Jakafi (ruxolitinib) (PMID: 29025600). | 29025600 |
PubMed Id | Reference Title | Details |
---|---|---|
(29025600) | A novel somatic JAK2 kinase-domain mutation in pediatric acute lymphoblastic leukemia with rapid on-treatment development of LOH. | Full reference... |